Stock ARBUTUS BIOPHARMA CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Arbutus Biopharma Corp Nasdaq

Equities

CA87911B2093

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Arbutus Biopharma Corp
06-06 Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial MT
06-06 Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
AQ
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial
MT
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
GL
Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial
CI
Arbutus Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
AQ
Arbutus Biopharma : Corporate Presentation - June 2024
PU
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
GL
Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)
CI
Arbutus to Participate in Jefferies Global Healthcare Conference
GL
Arbutus to Present Imdusiran Data at EASL Congress 2024
AQ
Arbutus to Present Imdusiran Data at EASL Congress 2024
GL
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
AQ
Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma
CI
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care Stocks Softer Friday Afternoon
MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
MT
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
BU
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders
CI
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. Stock
  5. News Arbutus Biopharma Corp